Distal 17p13.1 microdeletion syndrome
dis-tal sev-en-teen pee thur-teen point one my-cro-dee-lee-shun sin-drome
Also known as: 17p13.1 microdeletion syndrome, 17p13.1 deletion syndrome
At a Glance
What is Distal 17p13.1 microdeletion syndrome?
Distal 17p13.1 microdeletion syndrome is a rare genetic disorder caused by the deletion of a small piece of chromosome 17. This condition primarily affects the nervous system, leading to intellectual disability and developmental delays. It is present from birth and can be identified through genetic testing. Early symptoms often include microcephaly, or a smaller than average head size, and distinctive facial features. As the child grows, they may experience difficulties with speech and motor skills. Early diagnosis is crucial to provide appropriate interventions and support. Families may face challenges related to the child's developmental needs and require ongoing medical and educational assistance. The prognosis varies, but with support, individuals can lead fulfilling lives. Daily life may involve regular therapies and educational accommodations. The condition does not typically affect life expectancy. Support groups and resources can help families manage the impact of the disorder. Awareness and understanding of the condition can improve outcomes for affected individuals.
Medical Definition
Distal 17p13.1 microdeletion syndrome is characterized by the deletion of genetic material on the distal end of the short arm of chromosome 17. The pathological mechanism involves the loss of multiple genes, which contributes to the clinical features observed in affected individuals. Histologically, there are no specific findings, as the condition is primarily diagnosed through genetic analysis. It is classified under chromosomal deletion syndromes and is considered a rare genetic disorder. Epidemiologically, it occurs in approximately 1 in 1,000,000 individuals. The disease course is stable, with symptoms present from birth and persisting throughout life, though supportive care can improve quality of life.
Distal 17p13.1 microdeletion syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Microcephaly manifests as a significantly smaller head size compared to peers. It is caused by abnormal brain development due to the deletion of genetic material in the 17p13.1 region. Over time, microcephaly can lead to developmental delays and intellectual disabilities. Daily life is affected as the individual may require special education and therapies to manage developmental challenges.
Distinctive facial features include a broad forehead, upslanting palpebral fissures, and a flat nasal bridge. These features result from the altered development of craniofacial structures due to the genetic deletion. As the individual grows, these features become more pronounced but do not typically worsen. They may affect social interactions, but do not usually impact physical health.
Intellectual disability is characterized by below-average cognitive functioning and adaptive behaviors. It occurs due to the disruption of genes involved in brain development and function. This symptom is typically apparent in early childhood and persists throughout life. It affects learning, communication, and daily living skills, necessitating tailored educational and support services.
Common
Developmental delay refers to slower than expected progress in reaching developmental milestones. It is caused by the genetic deletion affecting brain and nervous system development. The delay can vary in severity and may become more noticeable as the child grows. Early intervention with therapies can help improve skills and reduce the impact on daily life.
Hypotonia presents as reduced muscle tone, leading to floppiness and weakness. It results from neurological impairments associated with the genetic deletion. Hypotonia can improve with age but may persist, affecting motor skills and posture. Physical therapy can help strengthen muscles and improve motor function.
Seizures are episodes of abnormal electrical activity in the brain, leading to convulsions or altered consciousness. They occur due to the disruption of neuronal networks caused by the genetic deletion. Seizures may begin in childhood and vary in frequency and severity. Antiepileptic medications and regular monitoring can help manage seizures and reduce their impact on daily life.
Less Common
Hearing loss can range from mild to severe and affects the ability to hear sounds clearly. It may result from structural abnormalities in the ear or neural pathways due to the genetic deletion. Hearing loss can become more apparent as the child develops language skills. Hearing aids and speech therapy can help improve communication abilities.
Vision problems may include strabismus, refractive errors, or other ocular abnormalities. These issues arise from developmental anomalies in the eyes or visual pathways linked to the genetic deletion. Vision problems can affect learning and daily activities if not addressed. Regular eye examinations and corrective lenses or surgery can help manage these issues.
What Causes Distal 17p13.1 microdeletion syndrome?
Distal 17p13.1 microdeletion syndrome is caused by deletions affecting the PAFAH1B1 gene located on chromosome 17 at position p13.1. The PAFAH1B1 gene encodes the LIS1 protein, which is crucial for proper neuronal migration during brain development. Mutations in the PAFAH1B1 gene can lead to a truncated or misfolded LIS1 protein, impairing its ability to bind to dynein motor complexes. This disruption affects intracellular transport processes, particularly those involving the movement of organelles along microtubules. Consequently, there is a dysfunction in the positioning and migration of neurons, leading to cortical malformations. The altered neuronal architecture can affect synaptic connectivity and communication between neurons, contributing to intellectual disability and developmental delays. Neuroinflammation may be triggered as a secondary response to neuronal stress and damage, exacerbating neurological symptoms. White matter degeneration occurs due to disrupted axonal transport and myelination processes, impacting signal transmission efficiency. The specific pattern of symptoms, such as microcephaly and distinctive facial features, arises from the combination of neuronal migration defects and secondary structural brain changes. Variability in disease severity among patients can be attributed to the size of the deletion and the involvement of additional genes within the deleted region. Other genes in the deleted region may contribute to the phenotypic variability by affecting different cellular pathways. Genetic background and environmental factors may also influence the clinical presentation and progression of the syndrome. Understanding the precise molecular mechanisms and pathways affected by the deletion is crucial for developing targeted therapeutic strategies. Further research is needed to elucidate the full spectrum of molecular interactions disrupted by the 17p13.1 microdeletion. Early diagnosis and intervention can help manage symptoms and improve the quality of life for affected individuals.
How is Distal 17p13.1 microdeletion syndrome Diagnosed?
Typical age of diagnosis: Distal 17p13.1 microdeletion syndrome is typically diagnosed in early childhood, often after developmental delays or distinctive physical features prompt further investigation. Diagnosis is usually confirmed through genetic testing following initial clinical suspicion.
Clinicians look for microcephaly, distinctive facial features, and developmental delays. A detailed family and medical history is crucial to identify any hereditary patterns or related conditions. Physical examination may reveal specific facial dysmorphisms and growth abnormalities. This step helps to narrow down the differential diagnosis and determine the need for further testing.
Magnetic Resonance Imaging (MRI) of the brain is often used to identify structural abnormalities. Specific findings may include reduced brain volume or other atypical brain structures. These imaging results can support the clinical suspicion of a genetic syndrome. Imaging helps exclude other neurological conditions that might present with similar symptoms.
Routine blood tests may be ordered to rule out metabolic or other systemic conditions. No specific biomarkers are definitive for this syndrome, but abnormalities may suggest further genetic testing. Abnormal results in metabolic panels might prompt additional investigations. Laboratory tests guide the clinician on whether to proceed with genetic testing.
Chromosomal microarray analysis is used to detect deletions in the 17p13.1 region. Deletions or mutations in this region confirm the diagnosis of distal 17p13.1 microdeletion syndrome. Genetic testing results provide a definitive diagnosis and help in understanding the inheritance pattern. These results are crucial for family counseling and future family planning.
Distal 17p13.1 microdeletion syndrome Treatment Options
Anticonvulsants are used to manage seizures, a common symptom in this syndrome. These drugs work by stabilizing neuronal membranes and reducing excitability. Specific drugs like valproate or lamotrigine may be used based on individual response. Clinical evidence supports their efficacy in reducing seizure frequency, though they may not address other symptoms. Side effects can include dizziness, fatigue, and potential liver toxicity.
Techniques include motor skills training and coordination exercises. The goal is to improve physical function and enhance developmental milestones. Sessions are typically conducted weekly and adjusted based on progress. Outcomes are measured through improved motor skills and increased independence in daily activities. Long-term benefits include enhanced quality of life and reduced disability.
Indicated for severe craniosynostosis, which may occur in some patients. The procedure involves reshaping the skull to allow for normal brain growth. Expected benefits include reduced intracranial pressure and improved neurological function. Surgical risks include infection, bleeding, and the need for additional surgeries. Post-operative care involves monitoring for complications and ensuring proper healing.
The team includes neurologists, geneticists, physical therapists, and psychologists. Interventions focus on managing symptoms, improving quality of life, and supporting development. Psychosocial support involves counseling and community resources for families. Family education is essential for understanding the condition and managing daily challenges. Long-term monitoring includes regular assessments and adjustments to the care plan as needed.
When to See a Doctor for Distal 17p13.1 microdeletion syndrome
- Severe seizures — this is an emergency because it can lead to brain damage or death if not treated immediately.
- Sudden loss of consciousness — this is critical as it may indicate a severe neurological event.
- Difficulty breathing — this is an emergency as it can lead to respiratory failure and requires immediate medical attention.
- Persistent vomiting — this is concerning as it may lead to dehydration and requires medical evaluation.
- Unexplained weight loss — this is significant as it may indicate underlying health issues that need investigation.
- Frequent infections — this is concerning as it may suggest an immune deficiency and should be assessed by a doctor.
- Mild headaches — monitor frequency and intensity at home and consult a doctor if they worsen.
- Occasional fatigue — monitor energy levels and ensure adequate rest, consult a doctor if it persists.
Distal 17p13.1 microdeletion syndrome — Frequently Asked Questions
Is this condition hereditary?
Distal 17p13.1 microdeletion syndrome can be hereditary, following an autosomal dominant pattern. There is a 50% chance of passing the deletion to offspring if a parent is affected. De novo mutations, where the deletion occurs spontaneously, are also possible. Carrier status can have implications for family planning, and genetic counseling is recommended to understand risks and options. Genetic counseling can provide personalized risk assessments and discuss potential testing for family members.
What is the life expectancy for someone with this condition?
Life expectancy varies based on the severity of symptoms and associated health issues. Early intervention and supportive care can improve outcomes and quality of life. Mortality is often related to complications such as severe infections or neurological issues. Treatment can significantly enhance survival by managing symptoms and preventing complications. Realistic expectations should include ongoing medical care and support to address developmental and health challenges.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves genetic testing, such as chromosomal microarray analysis, to identify the microdeletion. The time from first symptoms to diagnosis can vary, often taking months to years due to the rarity of the condition. Specialists such as geneticists and neurologists are usually consulted. Delayed diagnosis can occur due to the subtlety of symptoms and lack of awareness among healthcare providers. Confirmation is achieved through genetic testing that identifies the specific deletion.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising studies focusing on gene therapy and targeted treatments. Novel approaches aim to address the genetic basis of the condition, though these are still in experimental stages. ClinicalTrials.gov is a resource for finding relevant trials, and discussing options with your doctor is crucial. Patients should ask about eligibility for trials and potential benefits and risks. New treatments may take years to become widely available, but ongoing research offers hope for future advancements.
How does this condition affect daily life and activities?
This condition can impact mobility and self-care, often requiring physical and occupational therapy. Educational challenges are common, necessitating individualized learning plans and support. Social and emotional difficulties may arise, affecting interactions and mental health. The condition can place a significant burden on families, requiring adjustments and support. Access to resources such as support groups and adaptive technologies can greatly enhance quality of life.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Microdeletion in distal 17p13.1: a recognizable phenotype with microcephaly, distinctive facial features, and intellectual disability.
Zeesman S, Kjaergaard S, Hove HD et al. · Am J Med Genet A · 2012 · PMID: 22753084
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-04-26